Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction

• Published in: Pharmacological research Vol. 204; p. 107210
• Main Authors: Nasrallah, Dima, Abdelhamid, Alaa, Tluli, Omar, Al-Haneedi, Yaman, Dakik, Habib, Eid, Ali H.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01-06-2024; Elsevier
• Subjects: Angiotensin Receptor Antagonists - adverse effects; Angiotensin Receptor Antagonists - therapeutic use; Animals; Cardiac remodeling; Cardiovascular disease; Diabetes; Heart Failure - drug therapy; Heart Failure - physiopathology; Humans; Neprilysin - antagonists & inhibitors; Renal disease; Renin angiotensin aldosterone system; Renin-Angiotensin System - drug effects; SGLT-2; Stroke Volume - drug effects; CRR; ANP; ACCF/AHA; CNP; BNP; RAAS; LVEF; Cardiovascular disease; Renal disease; HFpEF; ENaC; HFrEF; EGFR; NT-proBNP; ESC; CGMP; SNS; Cardiac remodeling; CKD; AT1; AT2; BMI; NYHA; SBP; EF; ACE; OR; HFimEF; HFmrEF; SGLT-2; Renin angiotensin aldosterone system; CVD; ARB; AHA/ACC/HFSA; ARNI; SCD; ACEi; QALY; ATN; Diabetes; HF; ADHF
• ISSN: 1043-6618; 1096-1186; 1096-1186
• DOI: 10.1016/j.phrs.2024.107210

Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome characterized by volume overload, impaired exercise capacity, and recurrent hospital admissions. A major contributor to the pathophysiology and clinical presentation of heart failure is the activation of the renin-angiotensin-aldosterone system (RAAS). Normally, RAAS is responsible for the homeostatic regulation of blood pressure, extracellular fluid volume, and serum sodium concentration. In HFrEF, RAAS gets chronically activated in response to decreased cardiac output, further aggravating the congestion and cardiotoxic effects. Hence, inhibition of RAAS is a major approach in the pharmacologic treatment of those patients. The most recently introduced RAAS antagonizing medication class is angiotensin receptor blocker/ neprilysin inhibitor (ARNI). In this paper, we discuss ARNIs’ superiority over traditional RAAS antagonizing agents in reducing heart failure hospitalization and mortality. We also tease out the evidence that shows ARNIs’ renoprotective functions in heart failure patients including those with chronic or end stage kidney disease. We also discuss the evidence showing the added benefit resulting from combining ARNIs with a sodium-glucose cotransporter-2 (SGLT-2) inhibitor. Moreover, how ARNIs decrease the risk of arrhythmias and reverse cardiac remodeling, ultimately lowering the risk of cardiovascular death, is also discussed. We then present the positive outcome of ARNIs’ use in patients with diabetes mellitus and those recovering from acute decompensated heart failure. ARNIs’ side effects are also appreciated and discussed. Taken together, the provided insight and critical appraisal of the evidence justifies and supports the implementation of ARNIs in the guidelines for the treatment of HFrEF.
[Display omitted]